Using prostate-specific antigen to eliminate unnecessary diagnostic tests: significant worldwide economic implications (Q40403574)

20 September 2017

1 reference

title

Using prostate-specific antigen to eliminate unnecessary diagnostic tests: significant worldwide economic implications (English)

1 reference

20 September 2017

Oesterling JE

1

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 September 1995

1 reference

20 September 2017

1 reference

20 September 2017

volume

46

1 reference

20 September 2017

issue

3 Suppl A

1 reference

20 September 2017

page(s)

26-33

1 reference

Prostate-specific antigen. Improving its ability to diagnose early prostate cancer

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980247-7

7 January 2021

Family history and the risk of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980247-7

7 January 2021

Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980247-7

7 January 2021

Relationship between prostate specific antigen, prostate volume and age in the benign prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980247-7

7 January 2021

Relationship between grade and stage of adenocarcinoma of the prostate and regional pelvic lymph node metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980247-7

7 January 2021

The contemporary incidence of lymph node metastases in prostate cancer: implications for laparoscopic lymph node dissection

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980247-7

7 January 2021

Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980247-7

7 January 2021

Pelvic lymphadenectomy can be omitted in selected patients with carcinoma of the prostate: development of a system of patient selection

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980247-7

7 January 2021

Utility of preoperative serumprostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980247-7

7 January 2021

The role of bone scanning in the assessment of prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980247-7

7 January 2021

Bone scanning and plasma phosphatases in carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980247-7

7 January 2021

Comparison of enzyme, clinical, radiographic, and radionuclide methods of detecting bone metastases from carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980247-7

7 January 2021

Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980247-7

7 January 2021

10.1016/S0090-4295(99)80247-7

Identifiers

DOI

1 reference

release_ivnwfskc2fhufnn4xir7it26vy

20 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ivnwfskc2fhufnn4xir7it26vy

24 November 2022

mapped directly with Wikidata item

1 reference